PRESS RELEASE: PARIS OCTOBER 21, 2011: "Believe it or not: how much can we rely on published data on potential drug targets? ". Read their paper for the answer!

We found a very interesting correspondence recently published in Nature Reviews Drug Discovery by three scientists at Bayer Healthcare that says with facts and figures what a lot of us have been thinking and saying for years about the pertinence of published data for drug targets discovery and validation.

Their title is crystal clear: "Believe it or not: how much can we rely on published data on potential drug targets? ". Read their paper for the answer!

To get the related document click on this link or copy this link: http://www.nature.com/nrd/journal/v10/n9/pdf/nrd3439-c1.pdf on your browser.

Isn't it time to think different and to consider disruptive innovative "B plans" to secure your research & development programs?

Best regards

Manuel Gea,
Co-founder & CEO BIO-MODELING SYSTEMS
Heuristic Systems Biology
26, rue Saint Lambert 75015
Paris, France +33683061272
manuel.gea@bmsystems.net
www.bmsystems.net
http://www.linkedin.com/pub/manuel-gea/0/360/22b

ABOUT BMSYSTEMS:
Being the first, and to date, the only company that succeeded to create validated in-silico heuristic models of complex human pathologies and physiological processes, we offer to pharma companies the possibility to generate new & pertinent hypotheses, stop in time existing programs and launch lower risks, novel therapeutics programs *without being obliged to change their existing R&D discovery processes.*

Created in 2004, and profitable since 2006, we designed a unique heuristic systems biology business offer to provide all our partners and clients with a simplified results-oriented research paradigm that alleviates global R&D/business issues.
Because we do not sell our technologies, but deliver their outputs in open formats, our clients are not dependent upon external proprietary technologies to maintain and update these new & pertinent hypotheses.

Because clients' proprietary data protection is critical, we do not use their proprietary data to generate the first version of a CADI*™ model, and we limit data transfers to experimentations results only during the CADI model's validation phase.
If you are interested to learn more about our recent achievements and possible collaborations in the fields of neurodegenerative diseases, psychiatric and cognitive disorders, infectious diseases and cancer we shall be happy to meet your company's representatives at Bio in Washington, June 27-30, 2011.

For more information about The Max Planck Institute of Psychiatry
For more information about PharmacoPsychiatry

Very sincerely,

Manuel Gea,
Co-founder & CEO
BIO-MODELING SYSTEMS Predictive Integrative Biology
26, rue Saint Lambert 75015 – Paris, France

+33683061272
manuel.gea@bmsystems.net
www.bmsystems.net
New: *Download our latest presentation*: www.bmsystems.net
* CADI™: Computer Assisted Deductive Integration